177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response

被引：5
|
作者：
Rahbar, Kambiz [1 ]
Boegemann, Martin [2 ]
Ahmadzadehfar, Hojjat [3 ]
机构：
[1] Univ Hosp Muenster, Dept Nucl Med, Munster, Germany
[2] Univ Hosp Muenster, Dept Urol, Munster, Germany
[3] Univ Hosp Bonn, Dept Nucl Med, Bonn, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2017年 / 44卷 / 01期
关键词：
PSMA-617; Radioligand therapy; mCRPC;
D O I：
10.1007/s00259-016-3530-2
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：166 / 167
页数：2
相关论文
共 50 条
  • [1] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
    Kambiz Rahbar
    Martin Bögemann
    Hojjat Ahmadzadehfar
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 166 - 167
  • [2] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response Reply
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Tripathi, Madhavi
    Bal, Chandrasekhal
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 168 - 169
  • [3] 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?
    Kambiz Rahbar
    Hojjat Ahmadzadehfar
    Martin Boegemann
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 513 - 514
  • [4] 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?
    Rahbar, Kambiz
    Ahmadzadehfar, Hojjat
    Boegemann, Martin
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (03) : 513 - 514
  • [5] Safety and efficacy of 177lu-PSMA-617 radioligand therapy in patients with mCRPC: A multicenter study.
    Rahbar, Kambiz
    Ahmadzadehfar, Hojjat
    Kratochwil, Clemens
    Baum, Richard P.
    Schmidt, Matthias
    Pfestroff, Andreas
    Prasad, Vikas
    Heinzel, Aelxander
    Ruf, Juri
    Eveslage, Maria
    Boegemann, Martin
    Fendler, Wolfgang
    Krause, Bernd J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [6] 177Lu-PSMA-617 vs Cabazitaxel in MCRPC
    不详
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (04) : 13N - 13N
  • [7] Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma
    Jueptner, Michael
    Marx, Marlies
    Zuhayra, Maaz
    Luetzen, Ulf
    [J]. NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2019, 58 (04): : 328 - 330
  • [8] Renal Function after Radioligand Treatment with 177Lu-PSMA-617
    Ngoc, Christina Nguyen
    Happel, Christian
    Davis, Karen
    Groener, Daniel
    Mader, Nicolai
    Mandel, Philipp
    Tselis, Nikolaos
    Gruenwald, Frank
    Sabet, Amir
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [9] Radiation Dosimetry in 177Lu-PSMA-617 Therapy
    Jackson, Price
    Hofman, Michael
    McIntosh, Lachlan
    Buteau, James Patrick
    Kumar, Aravind Ravi
    [J]. SEMINARS IN NUCLEAR MEDICINE, 2022, 52 (02) : 243 - 254
  • [10] A Hangover Under 177Lu-PSMA-617 Therapy
    Poterszman, Nathan
    Somme, Laura
    Bund, Caroline
    Hutt, Emilie
    Somme, Francois
    [J]. CLINICAL NUCLEAR MEDICINE, 2024, 49 (06) : 582 - 583
12345